SEB Asset Management AB Purchases New Stake in Catalyst Pharmaceuticals, Inc. $CPRX

SEB Asset Management AB acquired a new position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) in the first quarter, Holdings Channel.com reports. The institutional investor acquired 224,705 shares of the biopharmaceutical company’s stock, valued at approximately $5,564,000.

Other hedge funds have also added to or reduced their stakes in the company. Parkside Financial Bank & Trust grew its position in shares of Catalyst Pharmaceuticals by 17.6% during the 4th quarter. Parkside Financial Bank & Trust now owns 3,138 shares of the biopharmaceutical company’s stock valued at $73,000 after acquiring an additional 469 shares during the period. Oregon Public Employees Retirement Fund raised its holdings in shares of Catalyst Pharmaceuticals by 1.8% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 26,428 shares of the biopharmaceutical company’s stock worth $617,000 after purchasing an additional 472 shares during the period. Lifestyle Asset Management Inc. raised its holdings in shares of Catalyst Pharmaceuticals by 3.4% in the 4th quarter. Lifestyle Asset Management Inc. now owns 16,835 shares of the biopharmaceutical company’s stock worth $393,000 after purchasing an additional 553 shares during the period. Smartleaf Asset Management LLC lifted its stake in Catalyst Pharmaceuticals by 55.6% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,764 shares of the biopharmaceutical company’s stock valued at $41,000 after purchasing an additional 630 shares during the last quarter. Finally, ProShare Advisors LLC lifted its stake in Catalyst Pharmaceuticals by 3.2% in the fourth quarter. ProShare Advisors LLC now owns 22,499 shares of the biopharmaceutical company’s stock valued at $525,000 after purchasing an additional 702 shares during the last quarter. Institutional investors own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Stock Performance

CPRX opened at $31.49 on Thursday. The company has a 50 day moving average of $31.37 and a 200 day moving average of $27.21. Catalyst Pharmaceuticals, Inc. has a 12 month low of $19.05 and a 12 month high of $32.56. The company has a market cap of $3.86 billion, a PE ratio of 18.10, a price-to-earnings-growth ratio of 0.96 and a beta of 0.74.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on CPRX shares. Citigroup downgraded Catalyst Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their target price for the stock from $35.00 to $31.50 in a research report on Friday, May 8th. Stephens set a $32.00 price target on Catalyst Pharmaceuticals in a research report on Thursday, May 7th. Wall Street Zen downgraded Catalyst Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, May 9th. Oppenheimer lowered Catalyst Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Thursday, May 7th. Finally, HC Wainwright cut Catalyst Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their price objective for the company from $35.00 to $31.50 in a research note on Thursday, May 28th. Two analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $32.00.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).